The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.
复制标题

DOI:
10.1155/2009/373524
复制
发表时间:
2009
期刊:
影响因子:
2.9
通讯作者:
Sutinen J
Sutinen J
中科院分区:
医学3区
文献类型:
--
作者:
Sutinen J

文献摘要

参考文献

被引文献

相似文献

高效抗逆转录病毒疗法 (HAART) 相关代谢并发症包括脂肪萎缩(皮下脂肪组织 (SAT) 损失)和胰岛素抵抗。噻唑烷二酮类药物是胰岛素增敏的抗糖尿病药物,它会增加肥胖糖尿病患者的不良副作用,导致 SAT 升高。此外,曲格列酮可以改善患有各种形式脂肪营养不良的非艾滋病毒患者的脂肪萎缩和血糖控制。这些数据引发了 14 项临床试验,以检验噻唑烷二酮类药物是否可用于治疗 HAART 相关的代谢并发症。这些研究的结果表明,对脂肪萎缩性 SAT 的影响即使有,也非常有限,可能是由于正在进行的 HAART 否定了有益效果。对于不服用胸苷类似物的患者,这种益处可能更为突出。尽管对脂肪萎缩的效果不佳,但噻唑烷二酮类药物却改善了胰岛素敏感性。然而,尤其是罗格列酮对血脂造成有害影响。目前的数据没有提供使用噻唑烷二酮类药物治疗HAART相关的脂肪萎缩的证据,但治疗脂肪萎缩相关的糖尿病可能是有必要的。应在这些患者中研究噻唑烷二酮类药物在肝脂肪变性等新适应症中的作用。
Highly active antiretroviral therapy (HAART)-associated metabolic complications include lipoatrophy (loss of subcutaneous adipose tissue (SAT)) and insulin resistance. Thiazolidinediones are insulin-sensitizing antidiabetic agents which—as an untoward side effect in obese diabetic patients—increase SAT. Furthermore, troglitazone has improved lipoatrophy and glycemic control in non-HIV patients with various forms of lipodystrophy. These data have led to 14 clinical trials to examine whether thiazolidinediones could be useful in the treatment of HAART-associated metabolic complications. The results of these studies indicate very modest, if any, effect on lipoatrophic SAT, probably due to ongoing HAART negating the beneficial effect. The benefit might be more prominent in patients not taking thymidine analoges. Despite the poor effect on lipoatrophy, thiazolidin-ediones improved insulin sensitivity. However, especially rosiglitazone induced harmful effects on blood lipids. Current data do not provide evidence for the use of thiazolidinediones in the treatment of HAART-associated lipoatrophy, but treatment of lipoatrophy-associated diabetes may be warranted. The role of thiazolidinediones for novel indications, such as hepatosteatosis, should be studied in these patients.
DOI: 10.1086/518005
发表时间: 2007-06-15
影响因子: 6.4
作者:
Cavalcanti, Rodrigo B.;Raboud, Janet;Walmsley, Sharon
通讯作者: Walmsley, Sharon
DOI: 10.1016/s0140-6736(02)08094-7
发表时间: 2002-03-23
期刊: LANCET
影响因子: 168.9
作者:
Bastard, JP;Caron, M;Capeau, J
通讯作者: Capeau, J
DOI: 10.1016/s0140-6736(99)06102-4
发表时间: 1999-09-25
期刊: LANCET
影响因子: 168.9
作者:
Brinkman, K;Smeitink, JA;Reiss, P
通讯作者: Reiss, P
DOI: 10.1016/s0140-6736(00)02854-3
发表时间: 2000-10-21
期刊: LANCET
影响因子: 168.9
作者:
Carr, A;Cooper, DA
通讯作者: Cooper, DA
DOI: 10.1016/j.ejphar.2006.06.014
发表时间: 2006-08-21
影响因子: 5
作者:
Coll, Blai;van Wijk, Jeroen P. H.;Joven, Jorge
通讯作者: Joven, Jorge